Required fields are marked with *

Verification code

Sofosbuvir

{PARAM:[Name]}()
Category Hepatitis C Virus (HCV)
CAS 1190307-88-0
Description Sofosbuvir is a prodrug that is metabolized to the active antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-monophosphate and is currently being investigated in phase 3 clinical trials for the treatment of hepatitis C. Studies have profiled sofosbuvir as a nucleotide inhibitor of hepatitis C virus, exerting selective inhibitory effects towards HCV NS5B polymerase.
Quotation Now

Product Information

Synonyms PSI-7977; PSI 7977; PSI7977; GS7977; GS-7977; GS 7977; Sovaldi; N-[[P(S),2'R]-2'-deoxy-2'-fluoro-2'-methyl-P-phenyl-5'-uridylyl]-L-alanine, 1-methylethyl ester; Hepcinat; Hepcvir; Resof; SoviHep
IUPAC Name propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate
Molecular Weight 529.45
Molecular Formula C22H29FN3O9P
Canonical SMILES CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
InChI InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
InChIKey TTZHDVOVKQGIBA-IQWMDFIBSA-N
Purity >98%
Density 1.41±0.1 g/cm3
Solubility Soluble in DMF, DMSO, Ethanol, PBS
Appearance White Solid
Application Antiviral Agents
Storage Store at -20°C
Complexity 913
Exact Mass 529.16254467
Index Of Refraction 1.573
In Vitro When cathepsin A (CatA) is incubated with PSI-7977 or Sofosbuvir (PSI-7977) for 150 min, ~18-fold more PSI-352707 is formed when Sofosbuvir (PSI-7977) is the substrate compared with PSI-7976. Moreover, the catalytic efficiency for Sofosbuvir (PSI-7977) with CatA is ~30-fold higher than that for PSI-7976. The genotype coverage of Sofosbuvir (PSI-7977) by using GT 1b (Con1)-, 1a (H77)-, and 2a (JFH-1)-derived replicons and GT 1b chimeric replicons containing the NS5B region from the J6 GT 2a isolate and from GT 2b and GT 3a patient isolates is evaluated, Sofosbuvir (PSI-7977) inhibits the replication of these replicons with similar EC50s (between 16 and 48 nM), and is especially active against the chimeric replicon containing the J6 NS5B (EC50=4.7 nM). Sofosbuvir (PSI-7977) inhibits clone A (GT 1b) wild-type and S282T replicons with EC90 values of 0.42 and 7.8 μM, respectively. In the clone A replicon assay, Sofosbuvir (PSI-7977) produces anti-HCV activity with EC90 values 0.42 μM.
PSA 167.99000
Target HCV
XLogP3-AA 1

TAKE YOUR NEXT STEPS

Get Started With Our Industry Experience And Client-Centric Focus!

Talk to Us

Copyright © 2024 BOC Sciences. All rights reserved.